

# Electric tibial nerve stimulation to reduce incontinence in care homes

<b>Submission date</b> 17/04/2018	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 25/04/2018	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 23/11/2023	<b>Condition category</b> Signs and Symptoms	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Urinary incontinence is a distressing and embarrassing condition that occurs in around 70% of older people who live in nursing or residential care homes. It is common in those who have dementia, and it can have a major impact on an older person's dignity and quality of life. There is some evidence from small-scale studies that transcutaneous posterior tibial nerve stimulation (TPTNS) is a safe and acceptable way to help bladder problems. TPTNS involves placing two sticky pads (surface electrodes) on a person's ankle and connecting these to a small, pocket sized electrical stimulator. This sends an electric pulse to the nerve near the ankle which also controls the bladder and reduces the feeling of sudden urgency, giving more time to find a toilet. TPTNS also increases the volume of urine the bladder can hold, so it does not need to be emptied as often. Better quality evidence regarding the effectiveness of TPTNS on UI is needed before it is used for everyday treatment. The aims of this study are to find out whether a programme of TPTNS is an effective treatment for urinary incontinence in care home residents, and to assess the associated costs and consequences.

### Who can participate?

People living in care homes who have urinary incontinence and wear absorbent pads

### What does the study involve?

Participants are randomly allocated to receive either TPTNS or dummy treatment. Twelve treatments are given over a six-week period, each treatment lasting 30 minutes. The amount of urine leaked into pads over a 24-hour period is measured after the 6 weeks and again after 3 and 5 months, to see if leakage is reduced. Participants are also asked whether they feel their bladder leakage has changed and about any impact on their quality of life. The opinions of close family members and care home staff about the impact of TPTNS on the participants are also sought. The cost of providing this treatment is compared to the costs of providing continence care and pads, and the best ways to provide TPTNS treatment, long-term, are explored with care home staff.

### What are the possible benefits and risks of participating?

The benefits to participation are reduced levels of urinary incontinence and the associated improvement to quality of life that this will bring to participants. Participation is considered to

be low risk with the only side effect reported of TPTNS being mild skin irritation at the site of the electrodes. Hypoallergenic electrodes will be available for those with sensitive skin.

Where is the study run from?

1. Lillyburn Care Home (UK)
2. Mosswood Care Home (UK)
3. Stanely Park Care Home (UK)
4. New Thursby Care Home (UK)
5. Priors Court Care Home (UK)
6. Other care homes to be identified in Scotland & Northern England (UK)

When is the study starting and how long is it expected to run for?

July 2017 to June 2020

Who is funding the study?

NIHR Health Technology Assessment Programme (UK)

Who is the main contact?

Dr Catriona O'Dolan

catriona.odolan@gcu.ac.uk

## Contact information

### Type(s)

Public

### Contact name

Dr Catriona O'Dolan

### ORCID ID

<https://orcid.org/0000-0002-9765-2464>

### Contact details

Rm418 George Moore Building

Glasgow Caledonian University

Cowcaddens Road

Glasgow

United Kingdom

G4 0BA

+44 (0)141 3318012

catriona.odolan@gcu.ac.uk

## Additional identifiers

### ClinicalTrials.gov (NCT)

NCT03248362

### Protocol serial number

HTA 15/130/73

# Study information

## Scientific Title

ELEctric Tibial nerve stimulation to Reduce Incontinence in Care homes

## Acronym

ELECTRIC

## Study objectives

Is a programme of transcutaneous posterior tibial nerve stimulation (TPTNS) a clinically effective treatment for urinary incontinence (UI) in care home residents and what are the associated costs and consequences?

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

1. Scotland A Research Ethics Committee, 06/11/2017, ref: 17/SS/0117
2. Yorkshire & The Humber - Bradford Leeds Research Ethics Committee, 01/12/2017, ref: 17/YH/0328

## Study design

The research comprises:

1. A pragmatic, multicentre, placebo-controlled randomised parallel-group trial to compare effectiveness of TPTNS (n=250) with sham stimulation (n=250) to reduce UI in CH residents. Results from an internal pilot with 100-140 residents will determine progression to full trial
2. A longitudinal, mixed methods nested process evaluation investigating intervention fidelity and acceptability and qualitative components of the intervention and implementation support
3. Economic evaluation of TPTNS compared with usual continence care pathway

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Urinary incontinence

## Interventions

Transcutaneous posterior tibial nerve stimulation (TPTNS) is a form of peripheral neuromodulation. The tibial nerve, which lies immediately posterior to the medial malleolus is stimulated electrically using a portable TENS machine and two surface electrodes. The cathode electrode is positioned behind the medial malleolus and the anode 10cm cephalad to it. Standardised stimulation parameters are applied of 10 Hz frequency, 200µs-1 pulse width in continuous mode and stimulation intensity (mA-1) is adjusted on a session-by-session basis according to individual resident comfort levels.

Participants will be randomised to a treatment or sham (placebo) group. Randomisation will be computer allocated on a one to one basis in random permuted blocks of size two, four or six, with stratification by gender, severity of incontinence and centre.

Those in the treatment group will receive a 12 session programme (a total of 6 hours) of tibial nerve stimulation delivered in 30 minute sessions twice weekly over a 6 week period. Those in the sham group will receive 12 sessions of low intensity, sub-clinical stimulation of the lateral sub-malleolar area, positioned specifically on the lateral aspect to avoid the tibial nerve, which runs close to the skin surface behind the medial malleolus. The stimulation parameters are identical to the TPTNS treatment other than the intensity of the current which will be set at 4mA, rather than adjusted individually as it is in the TPTNS intervention group. The current will be initially increased until the resident reports feeling some sensation following which the current will be reduced down to 4mA. All residents will be informed that they may not feel anything with this intervention and that this is quite normal.

### **Intervention Type**

Device

### **Phase**

Not Applicable

### **Drug/device/biological/vaccine name(s)**

Not provided at time of registration

### **Primary outcome(s)**

Volume of urinary incontinence leaked over a 24 hour period, measured by subtracting dry pad weight from wet pad weight, at 6 weeks post randomisation

### **Key secondary outcome(s)**

Urinary outcomes:

1. Volume of urinary incontinence leaked over a 24 hour period, measured by subtracting dry pad weight from wet pad weight, at 12 and 18 weeks post randomisation
2. Number of pads used in 24 hours at 6, 12 and 18 weeks post randomisation
3. Patient Perception of Bladder Condition (PPBC questionnaire) at 6, 12 and 18 weeks post randomisation
4. Family Carer Perception of Bladder Condition (FC-PBC questionnaire) at 6, 12 and 18 weeks post randomisation
5. Staff Perception of Bladder Condition (S-PBC questionnaire) at 6, 12 and 18 weeks post randomisation
6. Minnesota Toileting Skills Questionnaire (MTSQ questionnaire) at 6, 12 and 18 weeks post randomisation

Quality of life outcomes:

1. Resident DEMQOL questionnaire at 6 and 18 weeks post randomisation
2. Proxy DEMQOL questionnaire at 6 and 18 weeks post randomisation

Economic outcomes:

Resource Use Questionnaire (RUQ) at 6 and 18 weeks post randomisation

Qualitative outcomes:

1. The experiences of the TPTNS intervention from the perspectives of residents, family carers

and care home staff

2. Factors affecting intervention implementation in the care home context and optimisation for sustainability

**Completion date**

30/06/2020

## Eligibility

**Key inclusion criteria**

Care home residents:

1. With self or staff reported urinary incontinence of more than once/week
2. Who use the toilet or toilet aid for bladder evacuation with or without assistance
3. Who wear absorbent pads to contain urinary incontinence

**Participant type(s)**

Other

**Healthy volunteers allowed**

No

**Age group**

Senior

**Sex**

All

**Key exclusion criteria**

1. Care Home (CH) residents with an indwelling urinary catheter
2. CH residents with symptomatic UTI
3. CH residents with PVRU volume more than 300ml
4. CH residents with a cardiac pacemaker
5. CH residents with treated epilepsy
6. CH residents with bilateral leg ulcers
7. CH residents with pelvic cancer
8. CH residents on the palliative care register
9. Non-English speakers

**Date of first enrolment**

01/02/2018

**Date of final enrolment**

20/08/2019

## Locations

**Countries of recruitment**

United Kingdom

England

Scotland

**Study participating centre**

**Lillyburn Care Home**

United Kingdom

G66 8BY

**Study participating centre**

**Mosswood Care Home**

United Kingdom

PA3 3FA

**Study participating centre**

**Stanely Park Care Home**

United Kingdom

PA2 6HJ

**Study participating centre**

**New Thursby Care Home**

United Kingdom

FY8 2RN

**Study participating centre**

**Priory Court Care Home**

United Kingdom

FY8 1AL

**Study participating centre**

**Other care homes to be identified in Scotland & Northern England**

United Kingdom

-

## **Sponsor information**

**Organisation**

Glasgow Caledonian University

ROR

<https://ror.org/03dvm1235>

## Funder(s)

**Funder type**

Government

**Funder Name**

Health Technology Assessment Programme

**Alternative Name(s)**

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

## Results and Publications

**Individual participant data (IPD) sharing plan**

The data sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		01/06/2021	28/06/2021	Yes	No
<a href="#">Results article</a>	Cost consequence analysis	22/11/2023	23/11/2023	Yes	No
<a href="#">Protocol article</a>	protocol	16/12/2019	18/12/2019	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No
<a href="#">HRA research summary</a>			26/07/2023	No	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes